Background
Methods
Paper section and topic | Item | Descriptor |
---|---|---|
Title and abstract
Design | 1 | → Interdisciplinary Diabetes Care Teams operating on the interface between primary and specialty care are associated with improved outcomes of care: Findings from the Leuven Diabetes Project. |
Introduction
Background | 2 | → Scientific background and explanation of rationale: see Background section → Clustering: randomization at GP-level, primary/secondary outcomes at patient level. → Randomized per practice; stratified |
Methods
Participants | 3 | → All 379 primary care physicians (PCP's) that actively execute their profession in the project region were invited to participate. → The only inclusion criterion for the PCP's is the agreement to bring in all their known patients with type 2 diabetes mellitus. In this way selection bias is prevented. Patients had to provide informed consent before their data could be transmitted for collection and analysis. Only patients with type 2 diabetes mellitus were be included in the study, regardless of their age. Patients who were not capable to provide informed consent were excluded from the study. → Data were collected on paper files and from medical records |
Interventions | 4 | → See methods section |
Objectives | 5 | → See methods section |
Outcomes | 6 | → The primary endpoints of the study were the proportion of patients reaching three clinical ADA-targets: (1) HbA1c < 7%; (2) SBD ≤ 130 mm Hg; (3) LDL-C < 100 mg/dl. Secondary endpoints were the mean improvements in individual parameters of 12 validated parameters, i.e. HbA1c, LDL-C, HDL-C, Total Cholesterol, SBP, Diastolic Blood Pressure (DBP), weight, physical exercise, healthy diet, smoking status, statin and anti-platelet therapy. |
Sample size | 7 | → The financer to the project imposes a sample size of minimal one third of the potential PCP's. Using the calculator of the university of Aberdeen, sample size for cluster trials was computed. With a significance level of 0.05 and assumed Intra Cluster Coefficient of 0.1, we calculated that 114 clusters with a cluster size of 20 gave 80% power to detect between AQIP and UQIP a 10% in the absolute difference in the proportion of patients achieving a 10% improvement in the primary biochemical endpoints. Based on the fitted mixed models the observed ICC values are: HBA1C: 0.0445, SBD: 0.0466, LDL Cholesterol: 0.0399. |
Randomization Sequence generation | 8 | → After the recruitment period, using computer-generated numbers, a researcher not involved the study and blind to the identity of the practices will perform a randomization stratified by practice size (solo/duo/group practice) and the presence/absence of an electronic medical recording system. |
Allocation concealment | 9 | → Program Manager - invitation, stratified. → To minimize the possibility of selection bias all patients within a cluster were included |
Implementation | 10 | → Allocation: Van Den Broeke Carine, researcher to the scientific team, → Enrollment: Borgermans Liesbeth, researcher to the scientific team, → Assignment: program manager |
Blinding (masking) | 11 | → No blinding was possible at physician level, (both groups presented as 'intervention'), but patients didn't know to which intervention arm their physician belonged. |
Statistical methods | 12 | → See methods section, sub-heading statistical analysis. |
Study design
Participants
Intervention
PATIENT | ||
---|---|---|
USUAL QUALITY IMPROVEMENT PROGRAM (UQIP) | ADVANCED QUALITY IMPROVEMENT PROGRAM (AQIP) | |
Patient education
| Medical assessments and education upon referral of the PCPs by diabetologist or Diabetes Care Team = internist, nurse educator, dietician and ophthalmologist | Medical assessments and education upon referral of the PCPs by diabetologist or Diabetes Care Team = internist, nurse educator, flying educator, dietician, ophthalmologist and health psychologist |
Promotion of self-management
| ---- | Education of patients in practice (by flying educator) |
---- | Education at patient's home (by flying educator) | |
---- | Counseling by health psychologist | |
---- | Structured educational materials from IDCT | |
---- | Structured educational materials from community organizations | |
---- | Group educational sessions for patients and family members | |
---- | Free access to blood monitoring tools for self-management |
PROFESSIONAL | ||
---|---|---|
USUAL QUALITY IMPROVEMENT PROGRAM (UQIP) | ADVANCED QUALITY IMPROVEMENT PROGRAM (AQIP) | |
Clinician education
| Distribution of treatment protocol | Distribution of treatment protocol |
Two post-graduate educational sessions | Four post-graduate educational sessions provided by diabetologist (opinion leader): | |
- Evidence based guidelines | Evidence-based guidelines and principles of shared care | |
- The use of insulin | The use of insulin | |
Patient-centered counseling | ||
Peer review | ||
Standard educational materials | Extended educational materials | |
---- | Inviting PCPs during IDCT meetings to discuss patient cases | |
---- | Providing structured communication forms to PCPs by IDCT | |
---- | Distribution of shared care protocol + referral indication | |
Feed-back
| At start and end of project: summary of clinical performance | Every 3 months: summaries of clinical performance |
---- | Every three months: benchmarking feed-back | |
Reminders
| Clinical reminders at start and end of project | Every three months: Clinical reminders |
---- | Every three months: Shared care reminders |
ORGANISATIONAL | ||
---|---|---|
USUAL QUALITY IMPROVEMENT PROGRAM (UQIP) | ADVANCED QUALITY IMPROVEMENT PROGRAM (AQIP) | |
Team changes
| Interdisciplinary Diabetes Care Team (IDCT) operating close to regular care | Active installment of Interdisciplinary Diabetes Care Team (IDCT) operating under supervision of a diabetologist from a University Hospital |
Diabetes Program manager providing logistic support to PCPs | ||
---- | Introduction of shared care protocol | |
Active encouragement by IDCT and scientific team of PCPs to use shared care protocol | ||
---- | Referral arrangements Active encouragement by IDCT and scientific team to adhere to referral arrangements | |
---- | Liaison activities by IDCT towards in-hospital diabetes care team in secondary care | |
---- | Involvement of independent pharmacists | |
Continuous quality improvement
| Quality Assurance Team | Quality Assurance Team |
Variables
Statistical analysis
Results
Participant flow
Overall results
Baseline characteristics of patients
IDCT users (n = 313) Mean (SD) | IDCT non-users (n = 2182) Mean (SD) | p | |
---|---|---|---|
Mean age (years) | 62.3 (11.5) | 68.5 (11.6) | <0.0001 |
Mean diabetes duration (years) | 6.5 (6.7) | 7.3 (7.1) | 0.0674 |
Female gender (%) | 46 | 52 | 0.0001 |
HbA1c (%) | 7.8 (1.6) | 7.1 (1.2) | <0.0001 |
SBP (mm Hg) | 136 (16) | 136 (16) | 0.8012 |
DBP (mm Hg) | 81.2 (8.6) | 79.3 (8.9) | 0.0002 |
T. Chol (mg/dl) | 197 (39) | 191 (41) | 0.0223 |
LDL-C (mg/dl) | 111 (32) | 108 (34) | 0.1181 |
HDL-C (mg/dl) | 53 (16) | 54 (15) | 0.4763 |
BMI | 30.4 (5.3) | 29.5 (5.3) | 0.0087 |
Duration of insulin therapy | 6.2 (7.3) | 7.9 (7.6) | 0.1820 |
Education level
| |||
Low education level (%) | 40 | 50 | 0.0002 |
High education level (%) | 20 | 17 | 0.0669 |
Proportion of patients with:
| |||
HbA1c < 8% | 62 | 84 | <0.0001 |
HbA1c < 7% | 37 | 57 | <0.0001 |
SBP ≤ 130 (mm Hg) | 48 | 50 | 0.4892 |
LDL-C < 100 (mg/dl) | 36 | 42 | 0.0621 |
Non smoker (%) | 88 | 85 | 0.3332 |
Healthy Diet (%) | 63 | 67 | 0.1201 |
Physical Exercise (%) | 59 | 52 | 0.3597 |
Aspirin/clopidogrel (%) | 35 | 37 | 0.0952 |
ACE/A2A treatment (%) | 31 | 34 | 0.1945 |
Statin (%) | 37 | 40 | 0.3424 |
Metformin if obesity (%) | 71 | 58 | 0.0008 |
Insulin (%) | 16 | 20 | 0.1063 |
Complications (microangiopathic) | 86 | 71 | 0.1351 |
Users of IDCT (AQIP) (n = 226) Mean (SD) | Users of the IDCT (UQIP) (n = 87) Mean (SD) | p | |
---|---|---|---|
HbA1c (%) | 7,72 (1.62) | 7,98 (1.59) | 0.2632 |
SBP (mm Hg) | 135,35 (15.28) | 138,85 (19.09) | 0.1752 |
DBP (mm Hg) | 80,69 (8.52) | 82,62 (8.72) | 0.3202 |
TCHoL (mg/dl) | 193,96 (39.51) | 204,01 (38.25) | 0.0494 |
LDL CHol (mg/dl) | 108,94 (32.56) | 115,19 (31.09) | 0.2304 |
HDL CHol (mg/dl) | 53,43 (15.83) | 53.51 (15.61) | 0.9089 |
BMI | 30,49 (5.22) | 30,17 (5.52) | 0.5399 |
Targets reached (%) | 85 | 75 | 0.1324 |
Smokers (%) | 88,35 | 85,9 | 0.5571 |
Healthy diet (%) | 62,36 | 63,89 | 0.8570 |
Physical exercise (%) | 55,07 | 69,23 | 0.0477 |
Aspirin/clopidogrel (%) | 36,56 | 37,21 | 0.7233 |
ACE/A2A treatment (%) | 68,72 | 65,12 | 0.4532 |
Statin treatment (%) | 40,09 | 27,91 | 0.0391 |
Use of IDCT in PCPs and patients
Type of service offered by IDCT | UQIP | AQIP |
---|---|---|
IDCT consultations | 87 patients (9.5%) referred by 40 PCPs (75%) 250 consultations (21%) | 226 patients (14.3%) referred by 61 PCPs (91%) 924 consultations (79%) |
Educator in primary care facility | 38 patients (4.1%) 94 consultations | 107 patients (6.8%) 256 consultations |
Educator at home or in PCP practice | NA | 40 patients (2.5%) 91 consultations |
Dietician | 40 patients (4.3%) 63 consultations | 138 patients (8.7%) 255 consultations |
Internal medical doctor | 29 patients (3.1%) 63 consultations | 79 patients (5.0%) 164 consultations |
Opthalmologist | 19 patients (2.1%) 30 consultations | 55 patients (3.5%) 85 consultations |
Health psychologist | NA | 18 patients (1.1%) 73 consultations |
Printed educational materials for patients | NA | 126 distributed |
Communication forms to PCPs | NA | 924 reports |
Free blood monitoring tools for patients with insulin therapy onset | NA | 107 distributed |
Group information sessions for patient and family | NA | 7 sessions, 310 participants from 14 physicians |
Outcomes in users and non-users of the IDCT
T0
120 physicians, 67 practices 2495 patients Mean (SD) |
T1
118 physicians, 65 practices 2256 patients Mean (SD) | Difference between T1-T0 | P | |
---|---|---|---|---|
HbA1c (%) | 7.15 (1.26) | 6.76 (0.95) | -0.39 | <0.0001 |
IDCT users | 7.78 (1.63) | 7.00 (1.09) | -0.78 | <0.0001 |
IDCT non-users | 7.05 (1.16) | 6.72 (0.92) | -0.33 | |
SBD (mm Hg) | 136 (16) | 133 (15) | -3 | <0.0001 |
IDCT users | 136 (16) | 133 (15) | -3 | 0.6335 |
IDCT non-users | 136 (16) | 133 (15) | -3 | |
DBD (mm Hg) | 79 (9) | 77 (9) | -2 | <0.0001 |
IDCT users | 81 (9) | 79 (9) | -2 | 0.6103 |
IDCT non-users | 79 (9) | 77 (9) | -2 | |
Tchol (mg/dl) | 192 (40) | 177 (37) | -5 | <0.0001 |
IDCT users | 196 (39) | 173 (38) | -23 | 0.0002 |
IDCT non-users | 192 (41) | 177 (37) | -15 | |
HDL-C (mg/dl) | 54 (16) | 55 (15) | +1 | 0.0006 |
IDCT users | 54 (16) | 55 (16) | +1 | 0.8242 |
IDCT non-users | 54 (15) | 55 (15) | +1 | |
LDL-C (mg/dl) | 108 (34) | 95 (32) | -13 | <0,0001 |
IDCT users | 110 (32) | 90 (33) | -20 | 0.0012 |
IDCT non-users | 108 (34) | 95 (32) | -13 | |
BMI (kg/m2) | 29.6 (5.3) | 29.3 (5.2) | -0.3 | <0,0001 |
IDCT users | 30.3 (5.4) | 30.0 (5.3) | -0.3 | 0.9737 |
IDCT non-users | 29.5 (5.2) | 29.2 (5.2) | -0.3 | |
Hba1c < 7%, | 54% | 67% | +13% | <0.0001 |
IDCT users | 37% | 57% | +20% | 0.07449 |
IDCT non-users | 57% | 69% | +12% | |
BMI < 25 kg/m2
| 18% | 20% | +2% | 0.00108 |
IDCT users | 15% | 18% | +3% | 0.7186 |
IDCT non-users | 19% | 21% | +2% | |
Non smokers | 86% | 89% | +3% | 0.023 |
IDCT users | 88% | 89% | +1% | 0.2675 |
IDCT non-users | 85% | 89% | +4% | |
Healthy nutrition | 67% | 75% | +8% | <0.0001 |
IDCT users | 63% | 77% | + 4% | 0.9885 |
IDCT non-users | 67% | 75% | +8% | |
Physical exercise | 53% | 60% | +7% | 0.00035 |
IDCT users | 59% | 71% | +12% | 0.3349 |
IDCT non-users | 52% | 59% | +7% | |
Aspirin/clopidogrel | 40% | 57% | +17% | <0.0001 |
IDCT users | 37% | 67% | +30% | 0.005644 |
IDCT non-users | 40% | 56% | +16% | |
ACE/A2A | 73% | 78% | +5% | <0.0001 |
IDCT users | 68% | 76% | +8% | 0.3954 |
IDCT non-users | 74% | 78% | +4% | |
Statins | 39% | 53% | +14% | <0.0001 |
IDCT users | 37% | 57% | +20% | 0.04431 |
IDCT non-users | 40% | 53% | +13% |
Estimate | StdErr | P-value | |
---|---|---|---|
HbA1c (%) | 0.0848 | 0.1476 | 0.5656 |
SBP (mm Hg) | 2.3901 | 2.2566 | 0.2896 |
DBP (mm Hg) | 0.4532 | 1.3308 | 0.7335 |
T. Chol (mg/dl) | 1.8074 | 5.379 | 0.7369 |
LDL-CL (mg/dl) | 0.1833 | 4.686 | 0.9688 |
HDL-C (mg/dl) | -1.4947 | 1.4404 | 0.2995 |
BMI | 0.0092 | 0.2799 | 0.9737 |
Targets (%) | -0.3404 | 0.4078 | 0.4039 |
Non smoker (%) | 1.0710 | 1.3691 | 0.4341 |
Health diet (%) | 0.4817 | 0.6984 | 0.4904 |
Physical exercise (%) | 1.0129 | 0.6550 | 0.1221 |
Aspirin/clopidogrel (%) | 1.3368 | 0.5702 | 0.0119 |
ACE/A2A treatment (%) | 1.4285 | 0.7558 | 0.0584 |
Statin treatment (%) | 0.2726 | 0.6341 | 0.1766 |